Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell ...
ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback